Codexis, Inc. (NASDAQ:CDXS - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 4,570,000 shares, an increase of 50.8% from the February 28th total of 3,030,000 shares. Based on an average daily volume of 843,500 shares, the short-interest ratio is presently 5.4 days. Approximately 5.7% of the shares of the stock are short sold.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. lifted its stake in shares of Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,783 shares during the last quarter. Wolverine Trading LLC bought a new stake in Codexis in the fourth quarter worth $56,000. Fiduciary Trust Co purchased a new position in Codexis during the fourth quarter worth $65,000. Intech Investment Management LLC bought a new position in Codexis during the third quarter valued at $66,000. Finally, Group One Trading LLC purchased a new stake in shares of Codexis in the fourth quarter valued at $73,000. Hedge funds and other institutional investors own 78.54% of the company's stock.
Codexis Price Performance
Shares of CDXS stock traded down $0.14 during trading hours on Thursday, hitting $2.35. The stock had a trading volume of 423,117 shares, compared to its average volume of 631,458. The stock's 50-day moving average price is $3.57 and its two-hundred day moving average price is $3.94. Codexis has a one year low of $2.24 and a one year high of $6.08. The stock has a market capitalization of $194.67 million, a price-to-earnings ratio of -2.70 and a beta of 2.12. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15.
Codexis (NASDAQ:CDXS - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The firm had revenue of $21.46 million for the quarter, compared to the consensus estimate of $27.41 million. Equities analysts forecast that Codexis will post -0.77 EPS for the current year.
About Codexis
(
Get Free Report)
Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
See Also
Before you consider Codexis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Codexis wasn't on the list.
While Codexis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
